OBJECTIVES: Cardiovascular disease (CVD) is the leading cause of death in Switzerland. Whereas the health impact of CVD is well described, the socio-economic impact and value of novel therapies, like PCSK9 inhibitors (PCSK9i), is less well understood. This study assesses the impact of CVD and the value of PCSK9i from a broad public health and societal perspective in Switzerland. METHODS: An open-cohort population-based Markov model was developed using available Swiss data. The age-dependent CV event rate distribution was calibrated to the observed events in 2016. The yearly number of CV events, total hours paid, unpaid activity lost, and associated socio-economic impact of PCSK9i utilization were predicted. RESULTS: The 78,026 CV events predicted in Switzerland in 2017 resulted in 3 billion CHF of direct healthcare costs. The socio-economic impact of paid-work hours lost resulting from these events was 6 billion CHF, and the caregiver- and unpaid-work lost (0.5 billion hours) were valued at 11 billion CHF. For the 133,768 PCSK9i-eligible patients, 5,594 major adverse cardiovascular events (MACE; myocardial infarctions, ischaemic strokes and cardiovascular deaths) could be avoided, which would result in healthcare cost savings of 0.33 billion CHF. PCSK9i usage was predicted to result in gains of 170 million CHF in paid-work and 0.65 billion CHF in unpaid-work settings. On average, for every 1 CHF invested in PCSK9i, 1.40 CHF was returned to society in avoided medical costs and monetary value of paid and unpaid work (net return-on-investment: 0.40 CHF). CONCLUSIONS: Through the potential to prevent MACE, the predicted net return-on-investment of PCSK9i outweighed the cost, contributing to the economic and social wellbeing in Switzerland. There is a need to broaden the perspective when assessing the impact of CVD to fully understand the value that novel technologies can bring to the economy.